Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
New Insights of Liver Cancer and Its Treatment
share announcement

New Insights of Liver Cancer and Its Treatment

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 8721

Special Issue Editors

Prof. Dr. WaiMing Tai

E-Mail Website
Guest Editor
1. National Cancer Centre Singapore, Singapore City, Singapore
2. Duke-NUS Medical School, Singapore City, Singapore
Interests: gastrointestinal malignancies; biomarker; novel therapeutics; translational personalized medicine
Prof. Dr. Joycelyn Lee

E-Mail Website
Co-Guest Editor
1. National Cancer Centre Singapore, Singapore City, Singapore
2. Duke-NUS Medical School, Singapore City, Singapore
Interests: hepatopancreatobiliary cancers; immuno-oncology; microbiome in cancer; supportive care

Special Issue Information

Dear Colleagues,

There has been an avalanche of novel insights pertaining to liver cancer and stage-dependent multimodality treatments. This has been possible with findings stemming from basic science, translational research, and clinical trials. This Special Issue of Current Oncology aims to provide reviews on novel insights of liver cancer and its treatment. We invite researchers to address either one of the following topics or a related topic:

  • Basic science of hepatocellular carcinoma.
  • Translational research.
  • Surgical techniques and transplantation.
  • Locoregional therapies.
  • Systemic therapies.
  • Predictive biomarkers.

Prof. Dr. WaiMing Tai
Prof. Dr. Joycelyn Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • basic science
  • translational research
  • preclinical models
  • predictive biomarkers
  • surgery
  • locoregional therapies
  • systemic therapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 962 KiB  
Article
Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis
by Kuan-Chun Hsueh, Cheng-Chun Lee, Pi-Teh Huang, Chih-Yu Liang and Shun-Fa Yang
Curr. Oncol. 2023, 30(3), 3206-3216; https://doi.org/10.3390/curroncol30030243 - 09 Mar 2023
Viewed by 1265
Abstract
Several studies have shown that liver resection (LR) confers better survival outcomes in intermediate- and advanced-stage hepatocellular carcinoma (HCC) patients. However, the postoperative recurrence rate is high, and little is known about the survival benefits of LR for recurrent HCC patients who have [...] Read more.
Several studies have shown that liver resection (LR) confers better survival outcomes in intermediate- and advanced-stage hepatocellular carcinoma (HCC) patients. However, the postoperative recurrence rate is high, and little is known about the survival benefits of LR for recurrent HCC patients who have already received systemic treatment. This study aimed to evaluate the impact of LR on recurrent advanced-stage HCC patients who received sorafenib as a systemic treatment. In this study, 147 advanced HCC patients were enrolled between 1 January 2012 and 31 December 2019. Two study groups were classified, based on whether they underwent LR or not. To reduce the possible selection bias, a propensity score matching (PSM) analysis was performed. The primary study endpoint was set as overall survival (OS), and the secondary endpoint was set as progression-free survival (PFS). Our study results revealed that advanced HCC patients who received sorafenib with LR had a longer OS than did those without LR, whether before or after PSM (15.0 months vs. 6.0 months, HR 0.45, 95% CI 0.31–0.67, p < 0.001; 15.0 months vs. 5.0 months, HR 0.46, 95% CI 0.28–0.76, p = 0.001). Similar results were obtained in PFS, before or after PSM (4.14 months vs. 2.60 months, HR 0.60, 95% CI 0.40–0.89, p = 0.01; 4.57 months vs. 2.63 months, HR 0.58, 95% CI 0.34–0.97, p = 0.037). Multivariate analysis showed that the experience of LR was independent of other factors associated with better OS and PFS, whether before or after PSM (p < 0.05). Therefore, advanced HCC patients who have undergone liver resection should be encouraged to continue sorafenib treatment to improve prognosis. Full article
(This article belongs to the Special Issue New Insights of Liver Cancer and Its Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 277 KiB  
Review
Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma
by Stephanie M. Woo, Alexandra V. Kimchy, Lynette M. Sequeira, Charles S. Dorris, Aiwu R. He and Amol S. Rangnekar
Curr. Oncol. 2022, 29(12), 9813-9825; https://doi.org/10.3390/curroncol29120771 - 13 Dec 2022
Cited by 8 | Viewed by 2501
Abstract
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great [...] Read more.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date. Full article
(This article belongs to the Special Issue New Insights of Liver Cancer and Its Treatment)
19 pages, 775 KiB  
Review
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
by Maple Ye Feng, Landon L. Chan and Stephen Lam Chan
Curr. Oncol. 2022, 29(8), 5489-5507; https://doi.org/10.3390/curroncol29080434 - 04 Aug 2022
Cited by 20 | Viewed by 4129
Abstract
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the only effective systemic treatment for [...] Read more.
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the only effective systemic treatment for more than ten years. It was not until 2017 that several breakthroughs were made in the development of systemic strategies. Lenvatinib, another multikinase inhibitor, stood out successfully after sorafenib, and has been applied to clinical use in the first-line setting. Other multikinase inhibitors such as regorafenib, ramucirumab and cabozantinib, were approved in quick succession as second-line therapies. Concurrently, immune checkpoint inhibitors (ICIs) have readily become established treatments for many solid tumors, including HCC. The most studied ICIs to date, target programmed cell death-1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These ICIs have demonstrated efficacy in treating advanced HCC. More recently, combination of bevacizumab and atezolizumab (ICI targeting PD-L1) was approved as the gold-standard first-line therapy. Combination of ICIs with nivolumab and ipilimumab was also approved in the second-line setting for those who failed sorafenib. At the moment, numerous clinical trials in advanced HCC are underway, which will bring continuous change to the management, and increase the survival, for patients with advanced HCC. Our review article: (1) summarizes United States Food and Drug Administration (US FDA) approved systemic therapies in advanced HCC, (2) reports the evidence of currently approved treatments, (3) discusses potential drugs/drug combinations being currently tested in phase III clinical trials, and (4) proposes possible future directions in drug development for advanced HCC. Full article
(This article belongs to the Special Issue New Insights of Liver Cancer and Its Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop